ClinicalTrials.gg
CompletedNCT06695117Updated May 5, 2026

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

A Phase 1/2 interventional study of IIV-HD and rC19 (dose 1) in COVID-19 Immunization and Influenza Immunization, sponsored by Sanofi. Completed at 12 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Sanofi · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
980
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Influenza, Human by Sanofi — 4 open to participants now, 6 under way, 1 of them phase 3. Influenza, Human · Sanofi.

Enrollment
28th of 126
980 · median 305
Started
2024
with 7 others
Phase 1/2
13 of 139
1 open now
Registered
127th of 139
by date

Among the 139 studies in Influenza, Human by Sanofi, this one is the 28th largest by enrollment of the 126 interventional ones that give a count, is one of 8 that started in 2024, is one of 13 in phase 1/2, and was the 127th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 139 studies in Influenza, Human by Sanofi are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Influenza, Human by Sanofi, or all of them as a file.
02

Study summary

Study VBT00001 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States.

The purpose of the study is to assess the safety and immunogenicity of IIV-HD (high-dose inactivated influenza vaccine) + rC19 (adjuvanted recombinant COVID-19 vaccine) vaccine comprised of IIV-HD combined with different recombinant Spike (rS) antigen levels of rC19 compared to IIV-HD alone, rC19 (dose 1) alone, and IIV-HD and rC19 (dose 1) (coadministered in opposite arms).

Placebo will be coadministered in the IIV-HD alone, rC19 (dose 1) alone, and IIV-HD + rC19 study groups to control for the number of injections and to maintain observer-blinding.

Thus, each participant will receive two injections at enrollment, one in each deltoid muscle.

Study details include:

  • The study duration will be approximately 12 months
  • Study intervention will be administered via a single intramuscular (IM) injection into the right and left deltoid muscles on D01
  • Dose escalation with sequential enrollment (sentinel cohort followed by main cohort for a given dose)
  • The visit frequency will be D01, D09 (telephone call), D30, D182 (telephone call), and D366 (telephone call)

Number of Participants:

Approximately 980 participants are expected to be randomized.

03

Conditions studied

  • COVID-19 Immunization
  • Influenza Immunization

Browse trials for

Keywords

  • COVID-19 Vaccine and Influenza Vaccine
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Inclusion criteria to be checked at Screening Visit

  • Aged 50 years or older on the day of inclusion
  • form has been signed and dated.
  • Able to attend all scheduled visits and to comply with all study procedures.
  • Participant must be able to receive an injection in the deltoid muscle of both arms.
  • Participant must have completed a primary vaccination series against SARS-CoV-2 and at least 1 booster with a locally authorized or approved COVID-19 vaccine.

Inclusion criteria to be checked at Visit 1 (D01):

  • Aged 50 years or older on the day of inclusion
  • Participants who are healthy or with pre-existing stable condition (defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 12 weeks before enrollment), as determined by medical evaluation including medical history and physical examination.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

    • Is of non-. To be considered of non-childbearing potential, a female must be for at least 1 year, or surgically sterile.

OR

  • Is of childbearing potential and agrees to use an effective method or abstinence from at least 4 weeks prior to study intervention administration until at least 4 weeks after study intervention administration.

A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) on the day of enrollment before the first dose of study intervention.

  • Informed consent form has been signed and dated.
  • Able to attend all scheduled visits and to comply with all study procedures.
  • Participant must be able to receive an injection in the deltoid muscle of both arms.
  • Participant must have completed a primary vaccination series against SARS-CoV-2 and at least 1 booster with a locally authorized or approved COVID-19 vaccine.

Exclusion Criteria:

Exclusion criteria to be checked at Screening Visit and at Visit 1 (D01):

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (for glucocorticoids, ≥ 10 milligrams/day of prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • Known systemic to any of the study intervention components, or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances .
  • Self-reported thrombocytopenia, contraindicating intramuscular injection, based on investigator's judgment.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection, based on investigator's judgment.
  • Chronic illness (1) that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion .
  • Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature ≥ 100.4°F) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion.
  • History of serious adverse reaction to any influenza or COVID-19 vaccines.
  • Personal or family history of Guillain-Barré syndrome.
  • Prior history of myocarditis, pericarditis, or myopericarditis.
  • Prior history of stroke, , or stroke risk factors, which may include untreated/uncontrolled hypertension, untreated/uncontrolled hyperlipidemia, active smoking, atrial fibrillation, and additional risk factors, based on investigator's judgment, which may include history of thromboembolic disease, obesity, cardiac structural or valvular abnormality, carotid stent placement, or family history of stroke..
  • Receipt of any vaccine in the 4 weeks preceding study intervention administration or planned receipt of any vaccine prior to the second blood draw (ie, approximately in the 28 days following study intervention administration .
  • Previous vaccination against influenza (in the previous 6 months) with an or marketed vaccine.
  • Previous vaccination against COVID-19 (in the previous 6 months) with an investigational or marketed vaccine OR history of COVID-19 in the previous 6 months .
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months.
  • Participation at the time of study enrollment (or in the 4 weeks preceding study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.
  • Deprived of freedom by an administrative or court order, or being in an emergency setting, or hospitalized involuntarily.
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.

    1. Chronic illness may include, but is not limited to, cardiac disorders, hypertension, pulmonary disease, renal disorders, auto-immune disorders, diabetes mellitus, psychiatric disorders, neurologic disorders, or chronic infection
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
980 participants (actual)

Study arms

  • Experimental
    Group 1: IIV-HD (in right or left deltoid) and placebo (in opposite deltoid)

    two IM injections on D01

    Biological: IIV-HD · Other: Placebo (0.9% NaCl)

  • Experimental
    Group 2: rC19 (dose 1) (in right or left deltoid) and placebo (in opposite deltoid)

    two IM injections on D01

    Biological: rC19 (dose 1) · Other: Placebo (0.9% NaCl)

  • Experimental
    Group 3: IIV-HD (in right or left deltoid) and rC19 (dose1) (in opposite deltoid)

    two IM injections on D01

    Biological: IIV-HD · Biological: rC19 (dose 1)

  • Experimental
    Group 4: IIV-HD + rC19 (dose 1) (in right or left deltoid) and placebo (in opposite deltoid)

    two IM injections on D01

    Biological: IIV-HD + rC19 (dose 1) · Other: Placebo (0.9% NaCl)

  • Experimental
    Group 5: IIV-HD + rC19 (dose 2) (in right or left deltoid) and placebo (in opposite deltoid)

    two IM injections on D01

    Biological: IIV-HD + rC19 (dose 2) · Other: Placebo (0.9% NaCl)

  • Experimental
    Group 6: IIV-HD + rC19 (dose 3) (in right or left deltoid) and placebo (in opposite deltoid)

    two IM injections on D01

    Biological: IIV-HD + rC19 (dose 3) · Other: Placebo (0.9% NaCl)

  • Experimental
    Group 7: IIV-HD + rC19 (dose 4) (in right or left deltoid) and placebo (in opposite deltoid)

    two IM injections on D01

    Biological: IIV-HD + rC19 (dose 4) · Other: Placebo (0.9% NaCl)

Interventions

  • BiologicalIIV-HD

    Inactivated, split-virion

  • BiologicalrC19 (dose 1)

    Protein subunit

  • BiologicalIIV-HD + rC19 (dose 1)

    IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit

  • BiologicalIIV-HD + rC19 (dose 2)

    IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit

  • BiologicalIIV-HD + rC19 (dose 3)

    IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit

  • BiologicalIIV-HD + rC19 (dose 4)

    IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit

  • OtherPlacebo (0.9% NaCl)

    Normal saline

06

What researchers measure

Primary outcomes

  1. Number of participants with immediate adverse events (AEs)

    Immediate adverse events are any unsolicited systemic adverse events reported in the 30 minutes after vaccination

    Time frame: Within 30 minutes after each vaccination

  2. Number of participants with solicited injection site reactions

    Solicited injection site reactions include injection site pain, erythema and swelling

    Time frame: Up to 7 each days after vaccination

  3. Number of participants with solicited systemic reactions

    Solicited systemic reactions include fever, headache, fatigue, myalgia and chills

    Time frame: Up to 7 days after each vaccination

  4. Number of participants with unsolicited AEs

    Unsolicited (spontaneously reported) AEs, not fulfilling criteria for solicited adverse reactions

    Time frame: Up to 28 days after each vaccination

  5. Number of participants with adverse events of special interest (AESIs)

    AESIs

    Time frame: Up to 180 days after each vaccination

  6. Number of participants with medical attended adverse events (MAAEs)

    MAAEs

    Time frame: Up to 180 days after each vaccination

  7. Number of MAAEs relating to predefined potential immune-mediated disease (PIMDs)

    MAAEs relating to predefined PIMDs

    Time frame: From D182 through 12 months following the last study vaccination

  8. Number of participants with serious adverse events (SAEs)

    SAEs

    Time frame: Up to 180 days after each vaccination

  9. Number of participants with related SAEs

    Related SAEs

    Time frame: From D182 through 12 months following the last study vaccination

  10. Number of MAAEs relating to predefined PIMDs that meet the criteria for SAEs

    MAAEs relating to predefined PIMDs that meet the criteria for SAEs

    Time frame: From D182 through 12 months following the last study vaccination

  11. Geometric mean (GM) of HAI titers in all participants

    HAI titers

    Time frame: At D01 and D30

  12. Geometric mean ratio (GMR) HAI titers ratio D30/D01 in all participants

    Individual HAI titers ratio D30/D01

    Time frame: At D01 and D30

  13. GM of SARS-CoV-2 neutralizing titers in all participants

    SARS-CoV-2 neutralizing titers

    Time frame: At D01 and D30

  14. GMR of SARS-CoV-2 neutralizing titers ratio D30/D01 in all participants

    Individual SARS-CoV-2 neutralizing titers ratio D30/D01

    Time frame: At D01 and D30

Secondary outcomes

  1. Percentage of participants with seroconversion in all participants

    Seroconversion is defined by: HAI titer \< 10 \[1/dil\] at D01 and post-injection titer ≥ 40 \[1/dil\] at D30 or HAI titer ≥ 10 \[1/dil\] and a ≥ 4-fold increase in titer \[1/dil\] at D30

    Time frame: At D30

  2. Percentage of participants with HAI titer ≥ 10 (1/dil) in all participants

    detectable HAI titer ≥ 10 (1/dil)

    Time frame: At D01 and D30

  3. Percentage of participants with HAI titer ≥ 40 (1/dil) in all participants

    HAI titer ≥ 40 (1/dil)

    Time frame: At D01 and D30

  4. Percentage of participants with seroresponse to SARS-CoV-2 in all participants

    Seroresponse to SARS-CoV-2 is defined by SARS-CoV-2 neutralizing titers ≥ 4-fold rise in SARS-CoV-2 neutralizing titers from D01 to D30

    Time frame: At D30

07

Study locations

12 sites
  • Simon Williamson Clinic - Birmingham- Site Number : 8400003
    Birmingham, Alabama 35211, United States
  • AES - DRS - Optimal Research Alabama - Huntsville Site Number : 8400006
    Huntsville, Alabama 35802-2568, United States
  • Orange Grove Family Practice- Site Number : 8400012
    Tucson, Arizona 85741, United States
  • Synexus Clinical Research US - The Villages- Site Number : 8400011
    The Villages, Florida 32162, United States
  • Synexus Clinical Research US - Atlanta- Site Number : 8400001
    Atlanta, Georgia 30328, United States
  • Synexus Clinical Research- Site Number : 8400004
    Chicago, Illinois 60602, United States
  • Synexus Clinical Research - St. Louis- Site Number : 8400010
    Creve Coeur, Missouri 63141, United States
  • Synexus Clinical Research - New York- Site Number : 8400007
    New York, New York 10017, United States
  • Optimal Research - Texas- Site Number : 8400002
    Austin, Texas 78705, United States
  • Synexus Clinical Research US - Dallas- Site Number : 8400005
    Dallas, Texas 75234, United States
  • Synexus Clinical Research US - San Antonio- Site Number : 8400009
    San Antonio, Texas 78229, United States
  • Synexus Salt Lake City Site Number : 8400008
    Salt Lake City, Utah 84106, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Apr 2026, 16 months.

Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 16 months is above that.

Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2024
First posted
Nov 19, 2024
StartActual
Nov 19, 2024
Primary completionActual
Apr 16, 2026
CompletionActual
Apr 16, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06695117
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 19, 2024
Start date
Nov 19, 2024
Primary completion
Apr 16, 2026
Completion
Apr 16, 2026
Last update
May 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion